Liquidia Corporation will pay Pharmosa $3.5 million up front plus as much as $157.75 million in milestone payments to extend their existing agreement related to L606 inhaled liposomal treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The deal also includes a license for the use of Pharmosa’s nebulizers for use with liposomal drug formulations.
In June 2023, Liquidia acquired the North American rights to L606 inhalation suspension; the expanded agreement adds “key markets in Europe, Japan and elsewhere.” Pharmosa is retaining the rights to market L606 in much of Asia, including China, Korea, and Taiwan; the Middle East; and North Africa.
Liquidia Chief Medical Officer Rajeev Saggar commented, “This is a great example of our approach to research and development in pulmonary hypertension. This partnership has the potential to be transformational for people living with PAH and PH-ILD, as it will combine Liquidia’s expertise as a leader in the field of pulmonary hypertension with Pharmosa’s deep experience in inhaled liposomal formulations. We are delighted by the interest from the global medical and patient communities, many of which lack access to inhaled formulations of treprostinil, as we prepare to initiate the L606 pivotal study in PH-ILD later this year. We are also encouraged by the recent scientific advice from the European Medicines Agency that supports our plan to proceed with the study as designed.”
Pharmosa President Pei Kan said, “This expanded partnership with Liquidia is a strong endorsement for our L606 programs and our contribution to the fight against pulmonary hypertension including PAH and PH-ILD. With more than 100,000 PAH and PH-ILD patients in the major countries outside North America, improvements of the treatment strategies in this region are essential since there is no approved treatment for PH-ILD outside the US. We believe Liquidia’s commitment to move quickly and execute its global clinical program will accelerate the potential for long-term value creation for both parties in this partnership.”
Read the Liquidia Corporation press release.
